Teachers Retirement System of The State of Kentucky Has $1.54 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Teachers Retirement System of The State of Kentucky decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 11.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 18,831 shares of the company’s stock after selling 2,489 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Vaxcyte were worth $1,542,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Capital Research Global Investors grew its position in Vaxcyte by 26.8% during the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company’s stock worth $508,393,000 after buying an additional 1,312,302 shares in the last quarter. Norges Bank acquired a new stake in shares of Vaxcyte during the 4th quarter worth approximately $90,069,000. Vanguard Group Inc. increased its position in shares of Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock valued at $979,184,000 after purchasing an additional 521,204 shares during the period. Franklin Resources Inc. raised its stake in shares of Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after purchasing an additional 324,560 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Vaxcyte in the fourth quarter worth $21,669,000. Institutional investors own 96.78% of the company’s stock.

Insider Activity at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 24,000 shares of company stock worth $1,946,720 over the last 90 days. Insiders own 3.10% of the company’s stock.

Vaxcyte Stock Down 4.6 %

Shares of NASDAQ PCVX opened at $32.92 on Friday. The company has a market cap of $4.24 billion, a price-to-earnings ratio of -7.16 and a beta of 1.26. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The firm’s 50-day simple moving average is $55.57 and its 200 day simple moving average is $80.12.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, equities analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of recent research reports. Evercore ISI upgraded shares of Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Bank of America dropped their price target on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Cantor Fitzgerald began coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an “overweight” rating for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.